Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2022 - 03 - 28 save search
Ozempic® 2.0 mg approved in the US for the treatment of type 2 diabetes
Published: 2022-03-28 (Crawled : 22:00) - globenewswire.com
NVO | $123.5 -0.32% 1M
|
Health Technology
|
| O: 2.86%
H: 0.47%
C: -0.72%
ozempic treatment diabetes
Neurocrine Biosciences Announces Regulatory Approval of Dysval® (valbenazine) for the Treatment of Tardive Dyskinesia in Japan
Published: 2022-03-28 (Crawled : 21:00) - prnewswire.com
NBIX | $134.295 1.94% 130K
|
Health Technology
|
| O: 0.16%
H: 0.51%
C: -0.94%
dysval treatment approval
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Published: 2022-03-28 (Crawled : 19:00) - biospace.com/
BHC | $8.525 -1.22% 190K
|
Health Technology
|
| O: -0.35%
H: 0.09%
C: -0.7%
CLSD | $1.29 64K
|
Health Technology
|
| O: 2.97%
H: 2.47%
C: -3.7%
xipere treatment macular
Dupixent (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
Published: 2022-03-28 (Crawled : 17:00) - biospace.com/
SNY | $46.2 0.59% 210K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
treatment dupixent children
Neurocrine Biosciences to Present Data on Treatment Patterns and Unmet Needs in Adult and Pediatric Patients Living with Classic Congenital Adrenal Hyperplasia at AMCP 2022
Published: 2022-03-28 (Crawled : 14:00) - biospace.com/
NBIX | $134.295 1.94% 130K
|
Health Technology
|
| O: -0.45%
H: 1.5%
C: 0.31%
treatment
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-03-28 (Crawled : 13:20) - biospace.com/
ALZN | $0.741 18K
|
Professional, Scientific, and T...
|
| O: -1.63%
H: 5.79%
C: 0.83%
al001 treatment dementia trial set alzheimer’s alzheimer's phase 1
NLS Pharmaceutics Announces Early Access Program (EAP) Allowing Patients with Idiopathic Hypersomnia to Receive Treatment with Mazindol ER
Published: 2022-03-28 (Crawled : 13:20) - biospace.com/
NLSP | $0.1415 17K
|
|
| O: -1.41%
H: 3.24%
C: -5.0%
treatment program
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Published: 2022-03-28 (Crawled : 13:00) - globenewswire.com
PRTA 4 | $21.63 -1.64% 49K
|
Health Technology
|
| O: 0.38%
H: 2.41%
C: -0.35%
prx012 treatment fda clearance disease antibody alzheimer alzheimer’s alzheimer's disease alzheimer's anti-amyloid beta
Hope Springs Eternal for Inflammatory Disease Treatments at AAD 2022
Published: 2022-03-28 (Crawled : 13:00) - biospace.com/
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: 0.8%
H: 0.39%
C: 0.11%
disease treatment
Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for the Treatment of Friedreich's Ataxia
Published: 2022-03-28 (Crawled : 12:20) - biospace.com/
MITO | $0.32 0.25%
|
Health Technology
|
| O: 2.92%
H: 2.95%
C: -3.91%
treatment fda drug elamipretide friedreich's ataxia designation friedreich’s ataxia
Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar® Gel (Repository Corticotropin Injection) in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context
Published: 2022-03-28 (Crawled : 11:00) - prnewswire.com
MNKKQ | News | $0.02
|
Manufacturing
|
| O: -1.31%
H: 1.77%
C: 1.15%
acthar treatment
Hydraulic Dosing Pump Market - 49% of Growth to Originate from APAC | Driven by Growing Adoption of Hydraulic Dosing Pump for Water & Wastewater Treatment | Technavio
Published: 2022-03-28 (Crawled : 10:00) - prnewswire.com
IR | $91.015 -0.29% 230K
|
Producer Manufacturing
|
| O: -0.16%
H: 0.48%
C: -0.2%
treatment growing growth market
Philips expands network of clinical partners to set new standard of care for the early diagnosis and treatment of lung cancer
Published: 2022-03-28 (Crawled : 10:00) - globenewswire.com
PHG | $20.35 -0.29% 160K
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: 0.0%
treatment care cancer set diagnostic
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
Published: 2022-03-28 (Crawled : 08:00) - biospace.com/
RLFTF | $1.32 1K
|
n/a
|
| O: -1.85%
H: 3.62%
C: 2.9%
treatment technology therapeutics
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
JAGX | $0.23 93.6% 310M
|
Health Technology
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PALI | $6.57 57.93% 19M
|
Manufacturing
BTTR | $7.61 49.22% 1.8M
|
Manufacturing
PRSO | $1.79 40.95% 38M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
MCBC | $13.755 38.52% 620K
|
Finance
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.